AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative ColitisPRNewsWire • 08/28/23
Trillion-Dollar Trio: These 3 Super Growth Stocks Will Dominate the Market by 2035InvestorPlace • 08/18/23
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in AdultsPRNewsWire • 08/17/23
Here are the stocks to buy and the ones to sell if interest rates stay high, says JefferiesMarket Watch • 08/16/23
My Top Dividend King to Buy and Hold for the Next 10 Years, and It Isn't Even CloseThe Motley Fool • 08/14/23